Cargando…
Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
Autores principales: | Sarzani, Riccardo, Giulietti, Federico, Di Pentima, Chiara, Filipponi, Andrea, Spannella, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233190/ https://www.ncbi.nlm.nih.gov/pubmed/32424634 http://dx.doi.org/10.1007/s11739-020-02365-5 |
Ejemplares similares
-
The Identikit of Patient at Risk for Severe COVID-19 and Death: The Dysregulation of Renin-Angiotensin System as the Common Theme
por: Sarzani, Riccardo, et al.
Publicado: (2021) -
Renin-Angiotensin-System Inhibitors Are Associated With Lower In-hospital Mortality in COVID-19 Patients Aged 80 and Older
por: Spannella, Francesco, et al.
Publicado: (2022) -
Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded “Double-Trouble” Lipid Profile in Overweight/Obese
por: Spannella, Francesco, et al.
Publicado: (2019) -
Effect of sacubitril/valsartan on renal function: a systematic review and meta‐analysis of randomized controlled trials
por: Spannella, Francesco, et al.
Publicado: (2020) -
The Number of Pills, Rather Than the Type of Renin–Angiotensin System Inhibitor, Predicts Ambulatory Blood Pressure Control in Essential Hypertensives on Triple Therapy: A Real-Life Cross-Sectional Study
por: Sarzani, Riccardo, et al.
Publicado: (2021)